ArticleDermatology practical & conceptual2025
Age-related Survival Declines in Turkish Patients with Cutaneous Melanoma: A Retrospective Analysis.
Article in Dermatology practical & conceptual, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn cancer patients, the age of a patient at the time of diagnosis is considered among the important clinical indicators.
objectivesWe aimed to investigate this significance in melanoma patients by creating patient age groups.
methodsA total of 1,496 adult skin melanoma patients were evaluated retrospectively. Patients were divided into six age groups: under 30 (<30), 31-39 (30s), 40-49 (40s), 50-59 (50s), 60-69 (60s), and 70 and older (70+).
resultsThe median age was 52 years (range 16-104), and the most common age group was the 50s (n=340, 22.7%). As age increased, so did the Clark level (P=0.0001), the rate of ulceration (P=0.0001), and the rate of BRAF wild-type (P=0.002). The recurrence rates of early-stage patients were similar for all age groups. A significant overall survival (OS) advantage was found only between the following age groups: <30 and 60s (P=0.04) and <30 and 70+ (P=0.01). Five-year OS were, from young to old: 70.5%, 66%, 63.1%, 66.3%, 57.2%, and 46.8%. A significant OS advantage was found only between the following age groups: <30 and 60s (P=0.04) and <30 and 70+ (P=0.01). The 70+ group had significantly worse OS rates in all age groups (<30: P=0.0001; 30s P=0.0001; 40s: P= 0.001; 50s: P=0.0001; and 60s: P=0.04).
conclusionWhile some unfavorable histopathological prognostic factors are associated more frequently with increasing age, clinical stage and recurrence do not differ significantly between age groups. A possible explanation for this might be that the elderly have more comorbidities and die of different causes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.